Townsquare Capital LLC Purchases 7,053 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Townsquare Capital LLC lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,006 shares of the medical instruments supplier's stock after acquiring an additional 7,053 shares during the period. Townsquare Capital LLC owned approximately 0.24% of LeMaitre Vascular worth $5,068,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its stake in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 117 shares during the period. KBC Group NV boosted its holdings in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after buying an additional 410 shares during the last quarter. Huntington National Bank grew its position in LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after buying an additional 455 shares during the period. Finally, Empowered Funds LLC bought a new stake in LeMaitre Vascular in the fourth quarter worth about $150,000. Institutional investors and hedge funds own 84.64% of the company's stock.

Analysts Set New Price Targets

LMAT has been the topic of several research analyst reports. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital boosted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $95.25.

LeMaitre Vascular Stock Up 1.9 %

Shares of NASDAQ LMAT traded up $1.61 during trading on Friday, reaching $86.28. 184,020 shares of the company traded hands, compared to its average volume of 160,516. The stock has a market capitalization of $1.95 billion, a PE ratio of 47.15, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58. The firm has a 50 day simple moving average of $88.07 and a 200-day simple moving average of $93.51.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million during the quarter, compared to analysts' expectations of $55.99 million. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.93%. The ex-dividend date was Thursday, March 13th. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's payout ratio is 41.24%.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.